Dalmelitinib is a selective, orally active c-Met kinase inhibitor (IC50: 2.9 nM) that binds the ATP-binding region of c-Met. Dalmelitinib induces phosphorylation of MET and partially or completely inhibits phosphorylation of AKT and ERK. dalmelitinib exhibits a potent inhibitory effect on the proliferation of cancer cells (c-Met oncogene amplification) and can be used in cancer research (e.g. non-small cell lung cancer).